• No results found

Pharmacogenetics of antiemetics in Indonesian cancer patients Perwitasari, D.A.

N/A
N/A
Protected

Academic year: 2021

Share "Pharmacogenetics of antiemetics in Indonesian cancer patients Perwitasari, D.A."

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Pharmacogenetics of antiemetics in Indonesian cancer patients

Perwitasari, D.A.

Citation

Perwitasari, D. A. (2012, January 11). Pharmacogenetics of antiemetics in Indonesian cancer patients. Retrieved from https://hdl.handle.net/1887/18326

Version: Corrected Publisher’s Version License:

Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/18326

Note: To cite this publication please use the final published version (if

applicable).

(2)

1. Ondansetron and dexamethasone as standard antiemetics in cancer patients treated with highly emetogenic chemotherapeutic drugs is suboptimal for preventing chemotherapy- induced nausea and vomiting (this manuscript).

2. Variations in the genes encoding ABCB1 and 5-HTR3B or the CYP2D6 predicted phenotype do not predict ondansetron efficacy in Indonesian cancer patients (this manuscript).

3. The CTG haplotype of ABCB1 modifies metoclopramide efficacy in preventing delayed chemotherapy-induced nausea and vomiting (this manuscript).

4. The presence of chemotherapy-induced nausea and vomiting during the delayed phase causes deterioration in patients’ quality of life (this manuscript).

5. Gabapentin, an analogue of γ-aminobutyric acid, could be considered as an alternative antiemetic in combination with ondansetron and dexamethasone in cancer patients treated with highly emetogenic cytostatic drugs (Cruz et al., Support Care Cancer 2011 Apr 5 [Epub ahead of print]).

6. The collaboration between oncology pharmacists and medical oncologists should be developed to improve the management of chemotherapy-induced nausea and vomiting (Chan et al., J Oncol Pharm Pract 2008; 14(1):23-29).

7. The genetic variants of ABCB1, CYP2D6 and the 5-HT3B receptor play a role in explaining interindividual response of 5-Hydroxytriptamine-3B receptor antagonists in Caucasian patients (Ho et al., Current Opinion in Anaesthesiology 2006; 19(6):606-611).

8. The optimal antiemetic treatment in oncology will improve patients’ well-being and reduce the economic burden (Support Care Cancer 2011 Apr 7 [Epub ahead of print]).

9. Shortage of appropriate drugs causes deterioration of quality of life.

10. Obtaining a Doctor’s degree from two countries is a great leap which requires a lot of energy.

11. One purpose, hundred contributions.

Dyah A Perwitasari Leiden, 11 January 2012

Pharmacogenetics of Antiemetics in Indonesian Cancer Patients

belonging to the thesis entitled

Propositions

Referenties

GERELATEERDE DOCUMENTEN

The research presented in this thesis was performed at the Department of Clinical Pharmacy and Toxicology of Leiden University Medical Center, Leiden, The Netherlands, and the

27 In a clinical study with the the 5-HT3 receptor antagonists granisetron, tropisetron and ondansetron in cancer patients treated with moderately or highly emetogenic

Figure 2.1 Activation of emetic pathway by cytotoxic drugs and site of action of ant-emetic drugs. 5-HT, 5 Hydroxytriptamin; D 2 , dopamine; SP, substance P; H, histamine; M,

The aim of this study was to investigate the association of ABCB1, 5-HT3B receptor polymorphisms and CYP2D6- predicted phenotypes with ondansetron and metoclopramide

Conclusion: Indonesian cancer patients had significantly different AAGAG and AAGGG haplotype frequencies of the gene encoding the 5-HT3B receptor compared to healthy Caucasians..

Another study in Germany indicated that patients had different interpretations of health subscales of EORTC QLQ-C30, SF-36 and Functional Living Index Cancer Questionnaire

Patients with gynecological cancer in our study experienced severe symptoms, such as fatigue, nausea, vomiting, appetite loss and pain after chemotherapy despite adequate

10,16 Indeed, some studies in Caucasian cancer patients show that variability of the antiemetic response of ondansetron and tropisetron are related to the C3435T variant of the